Publication year | 2013 [2] | 2015 [9] | This study | This study | ||
---|---|---|---|---|---|---|
Cell line | ACHN | 786-O | SNU-228 | SNU-267 | ||
Age | 22 | 58 | 51 | 43 | ||
Sex | male | male | male | male | ||
Ethnicity | Caucasian | Caucasian | Korean | Korean | ||
Origin | metastasized tumor | primary tumor | primary tumor | primary tumor | ||
Cytology | adenocarcinoma | clear cell adenocarcinoma | clear cell adenocarcinoma | clear cell adenocarcinoma | ||
Drug exposure method | continuous | continuous | pulse | pulse | ||
Drug concentration | up to 10 μM | 5 μM | 3 μM | 5.5 to 7 μM | ||
Resistance indicator | IC50 | IC50 | GR100 | Efficacy | GR100 | Efficacy |
Fold increase | ||||||
 Sunitinib | 5 | 3.1 | 3.16 | 0.82 | 1.70 | 0.89 |
 Axitinib |  |  | 3.47 | 0.74 | 1.40 | 0.89 |
 Erlotinib |  | 4.5 |  |  |  |  |
 Lapatinib |  | 1.4 |  |  |  |  |
 Pazopanib |  | 1.6 | 1.79 | 0.85 | 1.16 | 0.89 |
 Sorafenib | 6 | 1.2 | 1.10 | 0.88 | 1.15 | 0.91 |
 Everolimus | 1 | 23 | 0.91 | 0.86 | 1.35 | 0.92 |
 Temsirolimus | 1 |  | 0.91 | 0.84 | 1.07 | 0.91 |